Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

The Ras Gene02:38

The Ras Gene

6.3K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

4.0K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
4.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

5.6K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

3.7K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Clinical Recommendations for Remote Robotic Assisted Surgery From the CRSA 2025 International Consensus Conference.

World journal of surgery·2026
Same author

New-Onset Type 2 Diabetes Mellitus and Cancer Risk: A Matched Cohort Study in China Kadoorie Biobank.

International journal of cancer·2026
Same author

Robotic versus Open Pancreatoduodenectomy (PORTAL): multicentre, single masked, phase 3, non-inferiority randomised controlled trial.

BMJ (Clinical research ed.)·2026
Same author

The surgical outcomes of modified Chen's U-suture technique compared with duct-to-mucosa anastomosis in laparoscopic pancreaticoduodenectomy: a multi-center cohort study.

Surgical endoscopy·2026
Same author

Development of a Modified Textbook Outcome in Evaluating Robot-Assisted Middle Pancreatectomy: A Real-World Study of RMP Surgery in a High-Volume Pancreatic Disease Center.

Cancer medicine·2026
Same author

LINC01137 facilitates pancreatic cancer stemness, chemoresistance and proliferation via the miR-7155-5p/KLF12/PI3K-Akt axis.

International journal of biological macromolecules·2026

相关实验视频

Updated: Jul 27, 2025

Reliably Engineering and Controlling Stable Optogenetic Gene Circuits in Mammalian Cells
09:20

Reliably Engineering and Controlling Stable Optogenetic Gene Circuits in Mammalian Cells

Published on: July 6, 2021

2.4K

针对KRAS的目标

Qi Ai1,2,3, Fanlu Li1,2,3, Siyi Zou1,2,3

  • 1Department of General Surgery, Pancreatic Disease Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Frontiers in immunology
|June 8, 2023
PubMed
概括

KRASG12V新抗原特异性T细胞受体 (TCR) 工程T细胞显示出治疗固体瘤的前景. 这项研究确定了一种针对CD4+T细胞中的KRASG12V的新型TCR,在中国人群中有效.

关键词:
在KRAS G12V突变中.工程T细胞受体-工程T细胞受体-T细胞人类白细胞抗原-DPB*0301人类白细胞抗原DPB*1401免疫疗法 免疫疗法固体瘤是一个固体瘤.

更多相关视频

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.0K
Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein
07:08

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein

Published on: January 16, 2020

5.8K

相关实验视频

Last Updated: Jul 27, 2025

Reliably Engineering and Controlling Stable Optogenetic Gene Circuits in Mammalian Cells
09:20

Reliably Engineering and Controlling Stable Optogenetic Gene Circuits in Mammalian Cells

Published on: July 6, 2021

2.4K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.0K
Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein
07:08

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein

Published on: January 16, 2020

5.8K

科学领域:

  • 在瘤学瘤学.
  • 免疫治疗是一种免疫疗法.
  • 分子生物学分子生物学

背景情况:

  • KRAS突变,特别是KRASG12V,是胰腺癌和结直肠癌等固体瘤的关键驱动因素.
  • 经TCR工程的T细胞提供了向癌症治疗方法,但HLA限制限制了它们在不同人群中的应用.
  • 开发特定于HLA的TCR对于有效的癌症免疫疗法至关重要,特别是在代表性不足的族群中.

研究的目的:

  • 为了识别和表征KRASG12V特异性T细胞受体 (TCR),用于潜在的癌症免疫疗法.
  • 在临床前模型中评估针对KRASG12V的TCR工程CD4+T细胞的疗效.
  • 为了解决中国人群中基于TCR的疗法对HLA的限制限制.

主要方法:

  • 从结直肠癌患者中鉴定KRASG12V特异性TCR.
  • 工程 CD4+ T 细胞与已识别的 TCR 针对 KRASG12V 的向.
  • 使用抗原呈现细胞 (APC) 和异种移植小鼠模型进行体外和体内疗效研究.
  • 通过IFN-γ分泌试验识别HLA亚型.

主要成果:

  • 确定了一种新的KRASG12V特异性TCR识别II类MHC.
  • 经TCR工程的CD4+T细胞,而不是CD8+T细胞,在体外和体内表现出显著的抗瘤疗效.
  • 该TCR特别针对HLA-DPB1*03:01和DPB1*14:01所呈现的KRASG12V,在中国人口中具有广泛的适用性.

结论:

  • 针对KRASG12V的TCR工程CD4+T细胞是固体瘤的可行治疗策略.
  • 鉴定的TCR受HLA-DPB1*03:01和DPB1*14:01的限制,克服了中国患者的HLA障碍.
  • 这种TCR对固体瘤的精密免疫疗法具有重大前景.